Saskatoon, Saskatchewan, July 30, 2024ZYUS Life Sciences Corporation (TSX-V: ZYUS), a Canada-based life sciences company focused on the development and commercialization of novel cannabinoid-based drug candidates for pain management, is pleased to announce that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a No Objection Letter (NOL) from Health Canada for a proof-of-concept (POC) study for its lead drug candidate, Trichomylin® softgel capsules.
The NOL signifies Health Canada’s concurrence that the safety information collected to date for Trichomylin® Softgel Capsules supports its use in the patient population. The objective of the POC study is to evaluate the preliminary efficacy and feasibility of Trichomylin® Softgel Capsules in patients with advanced cancer and moderate-to-severe cancer-related pain, and to de-risk ZYUS’ previously announced Phase 2 clinical trial.
About ZYUS Life Sciences Corporation
ZYUS (TSXV: ZYUS) is a life sciences company focused on developing and commercializing novel cannabinoid-based drug candidates for pain management. ZYUS strives to ensure intellectual property protection, defend innovative therapies and enhance shareholder value through rigorous scientific exploration and clinical research. ZYUS’ unwavering commitment extends to achieving regulatory approval of non-opioid-based pharmaceutical solutions with the aim of transforming patients’ lives. For more information, visit www.zyus.com or follow us on Twitter @ZYUSCorp.
Caution Regarding Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Company’s business, advancing its clinical research activities, obtaining regulatory approval for its cannabinoid-based drug candidates, introducing products that serve as alternatives to current pain management therapies such as opioids, and de-risking the previously announced Phase 2 clinical trial of Tricomyrin.® softgel capsules. Such forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “contemplates,” “believes,” “plans,” “projects,” “will” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Among other things, statements regarding our business, our ability to advance clinical research activities, obtaining regulatory approval for our cannabinoid-based drug candidates, the introduction of products that serve as alternatives to current pain management therapies such as opioids, and de-risking our previously announced Phase 2 clinical trial of tricomyrin may differ materially from those forward-looking statements.® All statements regarding Softgel Capsules are forward-looking information. These statements are not guarantees of future performance or results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those implied by these statements. Although these statements are based on management’s reasonable assumptions, there can be no assurance that the Company will achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results, except as required by applicable law.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730710496/ja/
contact address
For further information, please contact:
ZYUS Media Inquiry
media
1-833-651-7723
ZYUS Investor Relations
Investor Relations
